Jax DiEugenio

Enfortumab vedotin and pembrolizumab show promising first-line efficacy in treating recurrent metastatic head and neck cancer, with significant response rates.

Cemiplimab shows comparable second primary tumor rates to placebo while improving disease-free survival in high-risk cutaneous squamous cell carcinoma patients.

Fruquintinib plus sintilimab significantly enhances progression-free survival in advanced renal cell carcinoma, offering a promising second-line treatment option.

Pirtobrutinib shows significant improvements in patient-reported outcomes for relapsed CLL/SLL, outperforming standard therapies in a recent trial.

A phase 3 trial showed neoadjuvant mitomycin C before TURBT in NMIBC patients was safe. While 12-month recurrence-free survival was similar to standard care, an 18-month trend suggested a possible delayed benefit.

A retrospective study showed that either folate receptor alpha or B7-H4 was expressed in more than 80% of endometrial cancers evaluated.

Avelumab maintenance with axitinib interruption was feasible in metastatic renal cell carcinoma responders, according to updated phase 2 TIDE-A study results.

Avelumab plus best supportive care improved survival vs best supportive care alone in advanced urothelial carcinoma, regardless of diabetes status.

Fruquintinib plus TAS-102 showed clinical activity in heavily pretreated metastatic colorectal cancer.

Preliminary findings from the phase 1 trial showed that GCC19CART, a novel CAR T-cell therapy, demonstrated clinical antitumor activity in patients with refractory metastatic colorectal cancer.

Dose reductions of liposomal irinotecan and oxaliplatin did not compromise overall survival in patients with metastatic PDAC on NALIRIFOX.

A novel, all-oral combination regimen of mezigdomide, tazemetostat, and dexamethasone demonstrated early signals of activity and a tolerable safety profile in patients with highly refractory multiple myeloma.

The ELECTRA trial found that the combination of elacestrant and abemaciclib was well-tolerated and showed promising clinical activity in patients with ER-positive, HER2-negative metastatic breast cancer who had previously received endocrine therapy and another CDK4/6 inhibitor.

Neoadjuvant chemotherapy prior to surgery and postoperative radiation therapy could improve organ preservation in patients with T3 and T4a nasal and paranasal sinus squamous cell carcinoma.

Fianlimab combined with cemiplimab demonstrated persistent and significant clinical activity in patients with advanced melanoma, regardless of LAG-3 or PD-L1 expression.

Zanidatamab combined with chemotherapy demonstrated promising antitumor activity and safety in the first-line treatment of HER2-positive mCRC, with a high response rate and manageable adverse effects.

Findings from a real-world study showed that zanubrutinib was associated with lower rates of treatment switching and patients receiving subsequent therapy compared with acalabrutinib and ibrutinib in patients with CLL or SLL.